Tonganoxie, KS, March 09, 2015 --(PR.com
)-- Biomedical Devices of Kansas, LLC, of Tonganoxie, Kansas, has entered into an agreement with a Missouri firm to manufacture an injectable collagen for the European market.
Biomedical Devices of Kansas and EternoGen Aesthetics, LLC, a Columbia-Missouri-based company, are launching a bio-dermal restoration treatment to directly restore lost dermal collagen. The treatment will use rapid polymerizing collagen (RPC) to be injected in facial features. Collagen is responsible for the skin’s strength, texture and elasticity and is the most abundant protein in the human body.
According to Global Industry Analysts, Inc., the global market for collagen and HA-based biomaterials is forecast to reach $3.7 billion by the year 2017, due to heightened interest in personal healthcare and the growing size of the aging population.
William Graveman, president of Biomedical Devices of Kansas, said, “We are pleased to be working with EternoGen and our friends in the I-70 bioscience corridor to provide this commercial-scale product. It is very gratifying to bring this partnership to Tonganoxie.”
Luis Jimenez, president and COO of EternoGen Aesthetics, said “We are excited to collaborate with a local company to move the company to the next stage of production as we prepare for European launch. Our partnership with Biomedical Devices of Kansas creates significant value for our company and is a great milestone.”
Biomedical Devices of Kansas, LLC, is a contract design and manufacturing company servicing the healthcare technology industry and is a full-service resource for start-up biomedical and biotechnology development. EternoGen, LLC, was founded in 2009 by an academic research group from the University of Missouri. It is a post-trial stage medical device company that develops liquid collagen tissue products.